Atopic Dermatitis, Pregnancy Related
Conditions
Keywords
ruxolitinib, Atopic Dermatitis, pruritus, eczema, topical therapy, JAK inhibitor
Brief summary
This observational (enrollment into the registry while the pregnancy is ongoing) study is being conducted to compare the frequency of major congenital malformation (MCM)s among infants of women exposed to ruxolitinib cream during pregnancy with infants of women not exposed to ruxolitinib cream during pregnancy.
Detailed description
This study is an exposure cohort study of women within the US with AD who were exposed to ruxolitinib cream at any time during their pregnancy period, defined as up to 24 days prior to the estimated date of conception (DOC) through the end of pregnancy, compared with women in the US with Atopic Dermatitis (AD) not exposed to ruxolitinib cream during pregnancy. The DOC is estimated to occur 14 days after the last menstrual period (LMP). Eligible pregnant women may self-enroll or voluntarily be enrolled by their health care provider (HCP) by calling Syneos Health. Enrollment should occur as early in pregnancy as possible.
Interventions
DRUGRuxolitinib Cream
Ruxolitinib Cream
Sponsors
Incyte Corporation
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
15 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* Women, aged 15 to 50 years, with confirmed diagnosis of mild to moderate AD. * Ability to comprehend and willingness to give informed consent for the study; a legal minor needs parental or legally authorized representative's consent. * Prospective enrollment (ie, enrollment into the registry while the pregnancy is ongoing) or retrospective enrollment (ie, enrollment into the registry within 12 months of pregnancy outcome). * Information available to confirm eligibility for either the exposed to ruxolitinib cream cohort or the not exposed to ruxolitinib cream cohort. * Ruxolitinib cream cohort: consisting of pregnancies in women with AD and exposure to at least 1 application of ruxolitinib cream during the pregnancy period. * Nonexposed cohort: consisting of pregnancies in women with AD but not exposed to ruxolitinib cream during the pregnancy period * Reporter (eg, participant, maternal HCP) contact information available to allow for follow-up. * Permission to contact the participant's and her infant's HCPs.
Exclusion criteria
* If no longer pregnant and pregnancy outcome occurred more than 12 months prior to enrollment. * Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) before enrollment with another investigational medication or current enrollment in another investigational drug study. * Any pregnancy that is exposed to any other JAK inhibitor from 5 half-lives for the specific JAK inhibitor used from LMP through the end of the first trimester for MCMs or end of pregnancy for other outcomes.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of major congenital malformation (MCM)s | Up to 12 months after birth | Defined as any major structural or chromosomal defect in live-born infants, stillbirths or spontaneous losses equal to or greater than 20 weeks' gestation, or electively terminated pregnancies of any gestational age. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Pregnancy outcomes | Up to birth | Number of live births, still births, recognized spontaneous abortions and number of elective terminations as defined in the protocol. |
| Adverse pregnancy outcomes | Up to birth | Number of preterm births and maternal pregnancy complications as defined in the protocol. |
| Gestational Age | At time of delivery | Infant Gestational Age at birth as recorded in medical records. |
| Infant Sex | At time of delivery | Infant Sex at birth as recorded in the medical records. |
| Infant Body Weight | At time of delivery | Infant Body Weight at birth as recorded in medical records. |
| Number of minor congenital malformations | Up to 12 months after birth | Defined as abnormalities that do not significantly affect health and development, and normal variants are ascertained only among those who also have a major defect. |
| Infant Head Circumference | At time of delivery | Infant Head Circumference at birth as recorded in medical records. |
| APGAR Score | At time of delivery | One and five minute APGAR Scores at birth as recorded in medical records. |
| Number of small for gestational age (SGA)s | At time of delivery | Defined as a birthweight at or below the 10th percentile for a given gestational age. |
| Abnormal development | Through 12 months after birth | Based on Centers for Disease Control and Prevention (CDC) developmental milestones. |
| Infant Body Length | At time of delivery | Infant Body Length at birth as recorded in medical records. |
Countries
United States
Contacts
Primary ContactSyneos Health
Backup ContactIncyte Corporation Call Center (US)
Outcome results
None listed